IRVINE, Calif. (PRWEB) March 10, 2015
Nurotron Biotechnology Co., Ltd., will expand its organization ten-fold in 2015 with facilities and staff.
The company, which designs, develops and markets neural-electronic medical devices and systems, will construct a 323,000-square-foot complex in Zhejiang Hangzhou, China. Nurotron will house all administration, operations and manufacturing at the facility.
The new complex will replace Nurotron’s current 33,000-square-feet building, according to Chu Li, CEO of Nurotron. The business will increase its employee count to 3,000, up from the current staff of 300. “The expansion positions Nurotron for continued rapid growth,” says Li. “As the worldwide market for safe, reliable cochlear implant technology grows, Nurotron’s products are in much greater demand.” Production capability at the new plant will be 25,000 devices annually.
Nurotron’s Venus Cochlear Implant System is an effective solution for children and adults suffering from severe and profound hearing loss. The company holds the CE mark in Europe, and has received approval to sell in China, India and Turkey as well.
Nurotron Biotechnology Co., Ltd. (http://en.nurotron.com)
Nurotron Biotechnology is a medical device company that designs, develops and markets neural-electronic medical devices and systems. The company’s flagship system is the Venus Cochlear Implant System, a safe, reliable and effective solution for children and adults suffering from severe and profound hearing loss.
The global leader in cochlear implant technology maintains its research and development center in Irvine, Calif., and manufacturing facilities in China. Founded in 2006, Nurotron is headquartered in Hangzhou, China.